Wall Street analysts expect Atreca (NASDAQ:BCEL) to post earnings per share of ($0.66) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Atreca’s earnings. The company is scheduled to announce its next earnings report on Tuesday, February 11th.
According to Zacks, analysts expect that Atreca will report full year earnings of ($3.36) per share for the current year. For the next fiscal year, analysts anticipate that the firm will report earnings of ($3.14) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Atreca.
Atreca (NASDAQ:BCEL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.57) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.66) by $0.09.
Institutional investors and hedge funds have recently made changes to their positions in the company. Morgan Stanley bought a new position in Atreca in the second quarter worth approximately $43,000. Cubist Systematic Strategies LLC bought a new position in Atreca in the second quarter worth about $106,000. Point72 Hong Kong Ltd bought a new position in Atreca in the second quarter worth about $144,000. Pentwater Capital Management LP purchased a new stake in shares of Atreca during the second quarter valued at about $471,000. Finally, Parametric Portfolio Associates LLC purchased a new stake in shares of Atreca during the second quarter valued at about $499,000. 57.37% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:BCEL traded up $0.01 during trading on Friday, reaching $10.27. 211,800 shares of the company were exchanged, compared to its average volume of 100,253. The business’s fifty day simple moving average is $11.01. Atreca has a 12-month low of $9.59 and a 12-month high of $23.65.
Atreca Company Profile
Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Featured Story: Penny Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.